Everest Medicines enters global licensing agreement to develop and commercialize 3CL protease inhibitors from the Experimental Drug Development Center of Singapore as potentially the best COVID-19 oral antiviral treatments in the world


Everest obtains exclusive global rights to a series of 3CL protease inhibitors to treat COVID-19

Everest will have sublicence rights and full technology transfer

Authorization of Oral 3CL Protease Inhibitor Treatment Should Complement Everest’s COVID-19 Vaccination Program

Clinical trials evaluating the main active ingredient EDDC-2214 are expected to begin later this year

SHANGHAI, January 13, 2022 / PRNewswire / – Medicines from Everest(HKEX 1952.HK, “Everest”, or the “Company”), and that of Singapore The Center for the Development of Investigational Drugs (“EDDC”) today announced a global licensing agreement under which Everest will obtain the exclusive worldwide rights to develop, manufacture and commercialize the series of viral protease type 3C inhibitors (” 3CL ”) from EDDC as potentially best-in-class. COVID-19 Oral Antiviral Treatments. EDDC is that of Singapore national platform for drug discovery and development and is hosted by the Agency for Science, Technology and Research (“A * STAR”).

Under the terms of the agreement, Everest will obtain the exclusive worldwide rights to EDDC’s 3CL protease inhibitor series that have demonstrated potent in vitro activity against SAR-CoV-2 (the virus that causes COVID-19 ) and its variants, as well as other coronaviruses such as MERS. Everest has all the rights to further sub-license the drug and will benefit from a full technology transfer.

The lead compound is EDDC-2214, a new and potent SARS-CoV-2 3CL protease inhibitor, which Everest will develop as a COVID-19 oral antiviral therapy. The main protease of SARS-CoV-2 is the 3CL protease. Compared to several other COVID-19 oral antivirals, EDDC-2214 exhibits better in vitro potency and better preclinical oral bioavailability. Clinical trials evaluating EDDC-2214 are expected to begin later this year.

“EDDC-2214 and the potential future inhibitors of 3CL protease are new impactful actives that complement our existing COVID-19 vaccine program,” said Kerry Blanchard, MD, PhD, CEO of Everest Medicines. “We want to offer a COVID-19 package that includes both preventive vaccines and conveniently administered treatment for infections. This is a prime example of the innovative risk-sharing relationship Everest is building on a global scale. We intend to deliver the drug candidate quickly and effectively through clinical trials, in order to provide this novel oral antiviral therapy to patients during this time of limited treatment options. “

EDDC aims to develop therapies and diagnostics that save and improve the lives of patients in Singapore, Asia and all over the world. EDDC has already participated in several public-private efforts to develop COVID-19 diagnostics and therapies, including a program led by other public sector agencies to develop neutralizing monoclonal antibodies against COVID-19. The Center has demonstrated its strong capacity for collaboration with international partners and its proven competence in providing therapies and vaccines from research to clinical trials. In response to the global outbreak of the influenza A H1N1 (“H1N1”) virus, EDDC (through its legacy units, ETC and D3) worked with public and private partners to successfully develop that of Singapore first vaccine against H1N1 influenza with favorable immunogenicity. In addition, EDDC used its skills to integrate early discoveries into clinical development to support the development of a monoclonal antibody against dengue virus, named VIS513, in collaboration with an American biotechnology company Visterra Inc. Subsequently , the Visterra pipeline, including VIS513, was acquired by Otsuka Pharmaceutical for $ 430 million.

“This agreement with Everest allows us to harness the full potential of EDDC-2214 with the potential to deliver it to patients around the world,” said Prof. Damian o’connell, MD, PhD, CEO of EDDC. “Our team believes in Everest’s determination and ability to advance potentially best-in-class COVID-19 and pan-coronavirus therapies, and we are delighted to partner with Everest to make our shared vision a reality. . “

Under the terms of the transaction, EDDC will receive upfront payment and clinical and commercial milestone payments downstream, as well as typical royalties on net sales of products.

Everest is committed to ensuring that any therapy developed for COVID-19 will be accessible and affordable globally.

About Everest Medicines

Everest Medicines is a biopharmaceutical company focused on the development and commercialization of transformative pharmaceutical products that meet the critical unmet medical needs of patients in Asian markets. The Everest Medicines leadership team has deep expertise and extensive experience in high quality clinical development, regulatory affairs, CMC, business development and operations in both China and with the world’s leading pharmaceutical companies. Everest Medicines has built a portfolio of ten potentially global first-rate or blue-chip molecules, many of which are in advanced clinical development. The therapeutic areas of interest of the Company include oncology, autoimmune diseases, cardio-renal diseases and infectious diseases. For more information, please visit their website at www.everestmedicines.com.

About the Experimental Drug Development Center (EDDC)

The Experimental Drug Development Center (EDDC) is that of Singapore national platform for drug discovery and development, formed by the integration of the Experimental Therapeutic Center (CTE), Drug Discovery and Development (D3) and the Experimental Biotherapeutic Center (EBC) in 2019. EDDC aims to develop therapies and diagnostics that save and improve patients’ lives by Singapore, Asia and all over the world. EDDC works in collaboration with partners from the public sector and industry to translate the great science emerging from that of Singapore R&D in biomedical and clinical sciences in innovative health solutions.

About the Agency for Science, Technology and Research (A * STAR)

The Agency for Science, Technology and Research (A * STAR) is that of Singapore main R&D agency in the public sector. Through open innovation, we collaborate with our partners in the public and private sectors for the benefit of the economy and society. As a science and technology organization, A * STAR bridges the gap between academia and industry. Our research creates economic growth and jobs for Singapore, and improves lives by improving societal outcomes in healthcare, urban living and sustainability. A * STAR plays a key role in nurturing scientific talent and leaders for the broader research community and industry. A * STAR’s R&D activities range from biomedical sciences to physical sciences and engineering, with research entities mainly located in Biopolis and Fusionopolis. For current news, visit www.a-star.edu.sg.


View original content: https://www.prnewswire.com/news-releases/everest-medicines-enters-into-a-global-licensing-agreement-to-develop-and-commercialize-singapores-experimental-drug-development – 3cl-protease-inhibitor-centers-as-potentially-best-in-class-oral-antiviral-covid-19-treatments-wor-301460709.html

SOURCE Everest Medicines


Comments are closed.